Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Betaxolol.

I Goldberg1

  • 1Glaucoma Clinic, Prince of Wales Hospital, Randwick, Australia.

Australian and New Zealand Journal of Ophthalmology
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Beta-blockers treat glaucoma by lowering eye pressure. While timolol is common, its side effects limit use. Betaxolol offers a safer alternative for many patients, though caution is still advised.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dermoscopy of blastic plasmacytoid dendritic cell neoplasm in two patients.

Clinical and experimental dermatology·2021
Same author

Symptomatic mucosal involvement in pachyonychia congenita: challenges in infants and young children.

The British journal of dermatology·2019
Same author

Nested case-control study investigating the diagnostic role of tissue eosinophilia in adverse cutaneous drug reactions.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Grover disease and bullous pemphigoid: a clinicopathological study of six cases.

Clinical and experimental dermatology·2018
Same author

Punctate palmoplantar keratoderma: an unusual mutation causing an unusual phenotype.

The British journal of dermatology·2018
Same author

Topical pimecrolimus for paediatric cutaneous mastocytosis.

Clinical and experimental dermatology·2018
Same journal

Thomas a'Beckett Travers, 1902-1999.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Bowen's disease of the eyelid in a renal transplant recipient on immunosuppressants.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Linear IgA disease.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Ring keratitis from topical anaesthetic misuse.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Lamellar corneal autograft for corneal perforation.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Preretinal haemorrhages: an unusual manifestation of intravitreal amikacin toxicity.

Australian and New Zealand journal of ophthalmology·2000
See all related articles

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Beta-blockers are effective in treating glaucoma by reducing intraocular pressure.
  • Timolol, a non-selective beta-blocker, is widely used but has potential side effects.
  • These side effects, including reactive airways disease and cardiovascular conditions, limit timolol's use in certain patients.

Purpose of the Study:

  • To evaluate betaxolol, a selective beta-1 blocker, as an alternative to timolol for glaucoma treatment.
  • To compare the efficacy and safety of betaxolol with timolol.
  • To assess the potential additive effects of betaxolol with dipivefrin.

Main Methods:

  • Clinical evaluation of betaxolol's efficacy in lowering intraocular pressure.
  • Comparison of betaxolol's effectiveness against timolol.

Related Experiment Videos

  • Assessment of betaxolol's safety profile, particularly in patients intolerant to non-selective beta-blockers.

    • Main Results:

    • Betaxolol demonstrates comparable efficacy to timolol in reducing intraocular pressure for most patients.
    • Betaxolol may offer additive effects when used with dipivefrin.
    • Betaxolol appears safer for patients who cannot tolerate non-selective beta-blockers.

    Conclusions:

    • Betaxolol is a viable and potentially safer alternative for glaucoma patients who cannot tolerate non-selective beta-blockers like timolol.
    • While generally safer, betaxolol should still be used with caution due to the unpredictable risk of systemic side effects in susceptible individuals.
    • Further research may explore optimal combination therapies involving betaxolol.